Stay updated on TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial page.

Latest updates to the TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe record for a randomized Phase II trial of immunotherapy with or without radiotherapy in metastatic genitourinary cancers is displayed, including eligibility criteria, treatment arms, outcomes, and study dates.SummaryDifference54%

- Check16 days agoChange DetectedThe footer’s site revision changed from v3.7.2 to v3.8.0; the page content remains a 403 error.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide NIH announcement about website updates and terminology appears above the study record page’s 403 error.SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s ClinicalTrials.gov site revision number changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1; the page remains a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the previous study content. This prevents access to the ClinicalTrials.gov record for the NCT03115801 study, hindering users from viewing details.SummaryDifference19%

Stay in the know with updates to TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial page.